[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovulation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100646672","femiclock-non-invasive-tools-development-salivary-and-hair-progesterone-for-ovulation-detection-in-heathy-women-with-regular-menstrual-cycles-without-contraception-100646672",false,"NCT07687823","FemiClock: Non-invasive Tools Development (Salivary and Hair Progesterone) for Ovulation Detection in Heathy Women With Regular Menstrual Cycles Without Contraception.","FemiClock: Modeling Daily and Reproductive Parameters in Women: Proof of Concept and Feasibility of Analytical Methods for the Study of Female Fertility.","FemiClock","Inclusion Criteria:\n\n* Women aged 18 to 40 years, with a body mass index (BMI) between 19.0 and 29.9 kg\u002Fm². (Women with low or high BMI were excluded due to extensive literature showing a negative impact of extreme BMI values on the hypothalamic-pituitary-ovarian axis.)\n* Women not using hormonal contraception (or using a non-hormonal copper intrauterine device), or who discontinued hormonal contraception more than 3 months prior to enrollment and do not plan to resume contraception during the 3 study menstrual cycles.\n* Women with regular menstrual cycles between 25 and 35 days, with cycle length variability (difference between shortest and longest cycle) strictly less than 7 days.\n* Women owning a smartphone (to enable collection and transmission of data recorded by a study-provided smartwatch).\n* Exclusive daytime workers (no night or shift work).\n* Hair length greater than 5 cm from root to tip, and willingness to provide a hair sample.\n* Individuals affiliated with a national health insurance system or equivalent coverage.\n* Individuals able to understand the study objectives and risks and willing to provide written informed consent (dated and signed).\n\nExclusion Criteria:\n\n* Known fertility disorder.\n* Night work and\u002For shift work within the 6 months prior to enrollment (between 9:00 p.m. and 6:00 a.m.).\n* Untreated endocrine disorders or gynecological conditions that may affect menstrual cycles and\u002For ovulation, including clinical hyperandrogenism.\n* History of cancer within the past 5 years.\n* History of severe psychiatric disorder.\n* Current use of hormonal treatment or synthetic steroid therapy.\n* Self-reported pregnancy or breastfeeding within the past 3 months.\n* Participants currently in an exclusion period following participation in a previous clinical study.\n* Individuals under legal protection (guardianship, curatorship, or legal safeguard).\n* Inability to provide informed consent (e.g., emergency situation, cognitive or comprehension difficulties).\n* Desire for pregnancy within the 3 months following enrollment. The occurrence of pregnancy will not be considered an exclusion criterion; data collected during the menstrual cycle preceding pregnancy may still be analyzed, as it reflects a fertile cycle.\n\nExposure to potential endocrine disruptors will not be specifically assessed due to their high environmental prevalence and the complexity of their detection.",true,"FEMALE","18 Years","40 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","Currently, the gold standard to confirm ovulation is measuring LH and\u002For progesterone in blood.\n\nHowever, because confirmation requires a blood sample, this approach is not suitable for epidemiological studies evaluating the impact of various factors on ovulation.\n\nAdditionally, in cases of irregular menstrual cycles, there is additional difficulty in determining when the blood sample should be taken.\n\nOur objective is the development of non-invasive markers of ovulation (salivary and hair progesterone) in women with regular menstrual cycles over a period of 3 menstrual cycles. Our hypothesis is that there is a correlation between ovulation detection, using the \"gold standard\" i.e. detection of the pre-ovulatory LH surge associated with an increase in progesterone during the mid-luteal phase, and the mean level of hair progesterone measured between 2 menstrual cycles.\n\nVarious studies have shown that, to be functional, the female reproductive axis requires an intact circadian system characterized by the existence of biological clocks called \"clock genes\" which are expressed in 24-hour cycles. In rodent, mutations in these \"clock genes\" lead to irregular menstrual cycles and alterations in the preovulatory LH surge. A quantitative measurement (using quantitative RT-PCR) of clock gene expression in the oral cavity will be performed.\n\nSince the reproductive system is also under the influence of locomotor activity and diet, all of these parameters will also be analyzed using participants' smartphones and connected smartwatches.",[29,30,31],"Ovulation","Female Fertility","Menstrual Cycle",[33,34,35],"Progesterone","Circadian Clocks","Ovulation Detection","NOT_YET_RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-07","ACTUAL",{"date":42,"type":23},"2026-09-01",{"date":44,"type":23},"2028-03-01",{"name":46,"class":47},"University Hospital, Strasbourg, France","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100628788","phase-4-exogenous-progesterone-as-ovulation-trigger-100628788","NCT07466199","Exogenous Progesterone as Ovulation Trigger","Exogenous Progesterone as Ovulation Trigger - a Pilot Study","PRO-TRIGGER","Inclusion Criteria:\n\n* Informed Consent Form dated and signed correctly prior to the performance of any study procedure.\n* Oocyte donors aged \\>17 and \\\u003C34 years old in the moment of the recruitment.\n* Patients with regular menstrual cycles (between 25 to 35 days long).\n* Generally healthy women with no history of endocrine disorders (e.g., polycystic ovary syndrome (PCOS) or significant systemic disease).\n* Body Mass Index (BMI) between 18.5 and 28.\n\nExclusion Criteria:\n\n* Presence of ovarian cyst(s) detected on the baseline (initial) ultrasound examination.\n* Untreated endocrine conditions (polycystic ovary syndrome (PCOS), uncontrolled thyroid dysfunction and hyperprolactinemia).\n* Hypogonadotropic or hypergonadotropic hypogonadism.\n* Known hypersensitivity or clinical contraindication to the administration of vaginal progesterone or its excipients. This includes, but is not limited to: active deep vein thrombosis or thromboembolic disorders, known or suspected estrogen- or progesterone-dependent neoplasia, undiagnosed abnormal genital bleeding, porphyria, or severe hepatic dysfunction. Additionally, patients with anatomical abnormalities of the vagina that preclude the proper insertion or absorption of the vaginal insert are excluded.\n* Any condition contraindicating vaginal ultrasound and\u002For vaginal oocyte retrieval.These include: active pelvic inflammatory disease (PID), acute vaginal or cervical infection, or presence of pelvic malignancies. Patients with significant anatomical distortions or vascular anomalies in the pelvic region that, in the investigator's opinion, would make oocyte retrieval technically unfeasible or pose an unacceptable risk of hemorrhage or injury to adjacent organs, are also excluded.\n* Use of hormonal contraceptives (oral, patch, or ring) or GnRH analogues within the month preceding the study. Note: Participants who have discontinued these or other prohibited medications for a period of at least 30 days are eligible for rescreening starting at Visit 1.\n* Participation in any other ongoing clinical trial or use of investigational drugs within the last 30 days.","33 Years",{"count":58,"type":23},10,[60],"PHASE4","The goal of this clinical trial is to learn whether the sudden administration of vaginal micronized progesterone during the late follicular phase can trigger an LH surge and reactivation of oocyte meiosis in healthy oocyte donors aged 18 to 33 undergoing a mild ovarian stimulation cycle. The main question it aims to answer is:\n\n* Does progesterone administered in the late follicular phase induce an LH surge and subsequent oocyte meiosis reactivation?\n\nParticipants will:\n\n* Undergo a mild ovarian stimulation with 75 IU of follitropn alfa\n* Start vaginal micronized progesterone (400 mg every 12 hours) once at least one follicle reaches 15 mm\n* Have blood samples collected to measure hormone levels before and after progesterone administration\n* Undergo oocyte retrieval 35-36 hours after the progesterone trigger\n\nThis is a low-intervention, single-center pilot study including approximately 10 oocyte donors.",[29,63,64,65,66],"Ovarian Function","Assisted Reproductive Treatments","Oocyte Maturation","Hormonal Response",[68,69,33,65,70,71,72,73,74,75],"Trigger","Oocyte Donation","Luteinizing Hormone","LH Surge","Oocyte Retrieval","Oocyte Meiosis","Late Follicular Phase","Endocrinological profile","2026-06-02",{"date":78,"type":40},"2026-06-04",{"date":80,"type":23},"2026-07",{"date":82,"type":23},"2026-08",{"name":84,"class":85},"Instituto Valenciano de Infertilidade de Lisboa","NETWORK",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":17,"sex":93,"minAge":19,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":105,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":86},"100377597","apple-womens-health-study-100377597","NCT04196595","Apple Women's Health Study","Inclusion Criteria:\n\n* Have menstruated at least once\n* Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico)\n* Live in the United States of America\n* Be comfortable communicating in written and spoken English\n* Have installed the Apple Research app on your iPhone\n* Not share your iCloud account or iPhone with anyone else\n* Be willing and able to provide informed consent to participate in the study","ALL",{"count":95,"type":23},500000,"OBSERVATIONAL","This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research app(available on App Store), which allows a user to find, enroll, and participate in Apple-supported health-related research studies.",[31,29,99,100,101,102,103,104],"Menstruation","Polycystic Ovary Syndrome","Infertility","Menopause","Reproduction","Reproductive Health",[99,31,29,100,101,102,103,104],"RECRUITING","2024-07-01",{"date":109,"type":40},"2024-07-03",{"date":111,"type":40},"2019-11-14",{"date":113,"type":23},"2029-11",{"name":115,"class":116},"Apple Inc.","INDUSTRY"]